Anti-hepatocarcinoma Effects of Berberine-Nanostructured Lipid Carriers Against Human HepG2, Huh7, and EC9706 Cancer Cell Lines

Xiang-Ping Meng,Hua Fan,Yi-fei Wang,Zhi-ping Wang,Tong-sheng Chen

DOI: https://doi.org/10.1117/12.2245514

2016-01-01

Abstract:Hepatocarcinoma and esophageal squamous cell carcinomas threaten human life badly. It is a current issue to seek the effective natural remedy from plant to treat cancer due to the resistance of the advanced hepatocarcinoma and esophageal carcinoma to chemotherapy. Berberine (Ber), an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-hepatocarcinoma and antiesophageal carcinoma effects. However its low oral bioavailability restricts its wide application. In this report, Ber loaded nanostructured lipid carriers (Ber-NLC) was prepared by hot melting and then high pressure homogenization technique. The in vitro anti-hepatocarcinoma and antiesophageal carcinoma effects of Ber-NLC relative to efficacy of bulk Ber were evaluated. The particle size and zeta potential of Ber-NLC were 189.3 +/- 3.7 nm and -19.3 +/- 1.4 mV, respectively. MTT assay showed that Ber-NLC effectively inhibited the proliferation of human HepG2 and Huh7 and EC9706 cells, and the corresponding IC50 value was 9.1 mu g/ml, 4.4 mu g/ml, and 6.3 mu g/ml (18.3 mu/ml, 6.5 mu g/ml, and 12.4 mu g/ml mu g/ml of bulk Ber solution), respectively. These results suggest that the delivery of Ber-NLC is a promising approach for treating tumors.